Triazolam
- Generic Name
- Triazolam
- Brand Names
- Halcion
- Drug Type
- Small Molecule
- Chemical Formula
- C17H12Cl2N4
- CAS Number
- 28911-01-5
- Unique Ingredient Identifier
- 1HM943223R
Overview
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Background
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
Indication
For the short-term treatment of insomnia.
Associated Conditions
- Insomnia
Clinical Trials
FDA Approved Products
Halcion
Manufacturer:Pharmacia & Upjohn Company LLC
Route:ORAL
Strength:0.25 mg in 1 1
Approved: 2023/01/13
NDC:0009-0017
Triazolam
Manufacturer:Ingenus Pharmaceuticals, LLC
Route:ORAL
Strength:0.25 mg in 1 1
Approved: 2020/10/30
NDC:50742-646
Triazolam
Manufacturer:A-S Medication Solutions
Route:ORAL
Strength:0.25 mg in 1 1
Approved: 2021/02/01
NDC:50090-0522
Triazolam
Manufacturer:Aphena Pharma Solutions - Tennessee, LLC
Route:ORAL
Strength:0.25 mg in 1 1
Approved: 2017/11/16
NDC:43353-451
Triazolam
Manufacturer:Ingenus Pharmaceuticals, LLC
Route:ORAL
Strength:0.125 mg in 1 1
Approved: 2020/10/30
NDC:50742-645
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath